Compare XNCR & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XNCR | EFC |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2007 |
| Metric | XNCR | EFC |
|---|---|---|
| Price | $23.51 | $12.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $22.33 | $14.55 |
| AVG Volume (30 Days) | ★ 1.3M | 932.0K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 11.84% |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $125,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | $43.05 |
| P/E Ratio | ★ N/A | $10.65 |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $8.49 | $11.28 |
| 52 Week High | $30.61 | $14.12 |
| Indicator | XNCR | EFC |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 29.08 |
| Support Level | $11.20 | $12.37 |
| Resistance Level | $30.61 | $13.76 |
| Average True Range (ATR) | 1.45 | 0.19 |
| MACD | -0.70 | -0.07 |
| Stochastic Oscillator | 9.93 | 8.44 |
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.